FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1601694561> ?p ?o ?g. }

• W1601694561 abstract "Cancer has an enormous impact on the lives of patients and on society and there is an urgent need for improvements in therapy. In this thesis, early-clinical studies into both safety and pharmacokinetics of novel anti-cancer drugs as well as into circulating tumor cells (CTCs) are reported. Safety, tolerability and pharmacokinetics of pazopanib, a novel anti-cancer drug that targets new blood-vessel formation, was investigated in combination with oral topotecan, a topoisomerase-I inhibitor. Pharmacokinetic analysis showed that pazopanib increased the exposure to topotecan considerably, whereas topotecan did not increase exposure to pazopanib. The most frequently reported treatment-related side-effects were anemia, leukocytopenia, neutropenia and fatigue. In another study, dosing recommendations were established for oral topotecan in patients with renal impairment. The data currently available demonstrate that no dose adjustments are required in patients with prior platinum-based chemotherapy or mildly impaired renal function (2.3 mg/m2/day on days 1 to 5 in a 21-day cycle). Three studies investigated pharmacokinetics of eribulin mesylate, an intravenous drug derived from a marine sponge that interferes with cellular replication and division, leading to cell death. Dose recommendations were formulated for eribulin in patients with an impaired liver function (1.1 for Child-Pugh A and 0.7 mg/m2 for Child-Pugh B on days 1 and 8 of a 21-day cycle). The results of two other studies with co-administration of ketoconazole and rifampicin, respectively, on eribulin pharmacokinetics indicated that eribulin can be safely co-administrated with these drugs and that drug-drug interactions with other CYP3A4 inhibitors or inducers are not expected. The pharmacokinetic interaction between food and lapatinib, an oral tyrosine kinase inhibitor targeting the Epidermal Growth Factor Receptor 1 and 2 (EGFR and HER2), was also investigated. These observations can be put to use in dosing recommendations for use in clinical practice, which should lead to reduced drug toxicity. The second part of this thesis focused on CTCs. CTCs were detected by multi-marker quantitative polymerase chain reaction (QPCR) in peripheral blood samples from 20% of 82 early-stage breast cancer patients. Presence of CTCs predicted a significantly worse relapse-free survival (multivariate hazard ratio = 5.13 [95% CI: 1.62 – 16.31, P = 0.006]), compared to absence of CTCs. An exploratory study on the detection of CTCs in advanced NSCLC patients and healthy controls resulted in the development of an assay using QPCR to detect the presence of CTCs. Another assay was developed and validated using fluorescence activated cell sorting that enabled CTC detection, measurements of specific proteins in CTCs and their level of activation, CTC morphology and DNA content. Pharmacodynamics of activation of a specific protein (extracellular-signal-regulated kinase; ERK) down-stream of the EGFR signaling transduction cascade, as a marker for EGFR pathway inhibition, was also studied in CTCs of patients who were receiving an anti-cancer drug inhibiting activation of EGFR. This proof-of-principle demonstrated that CTCs can be used for pharmacodynamic analyses which can be applied in early-stage drug development." @default.
• W1601694561 created "2016-06-24" @default.
• W1601694561 creator A5084733864 @default.
• W1601694561 date "2011-11-30" @default.
• W1601694561 modified "2023-09-27" @default.
• W1601694561 title "Pharmacokinetics of novel anticancer drugs and dynamics of circulating tumor cells in early clinical studies" @default.
• W1601694561 cites W125031896 @default.
• W1601694561 cites W1536690700 @default.
• W1601694561 cites W1550111394 @default.
• W1601694561 cites W1556838039 @default.
• W1601694561 cites W1565978936 @default.
• W1601694561 cites W1592869430 @default.
• W1601694561 cites W1603230122 @default.
• W1601694561 cites W1783699960 @default.
• W1601694561 cites W1853173850 @default.
• W1601694561 cites W1859729923 @default.
• W1601694561 cites W1910056530 @default.
• W1601694561 cites W1922991603 @default.
• W1601694561 cites W1964301935 @default.
• W1601694561 cites W1964470226 @default.
• W1601694561 cites W1964743637 @default.
• W1601694561 cites W1965379690 @default.
• W1601694561 cites W1969895447 @default.
• W1601694561 cites W1970421475 @default.
• W1601694561 cites W1977131009 @default.
• W1601694561 cites W1979851514 @default.
• W1601694561 cites W1985610919 @default.
• W1601694561 cites W1986657548 @default.
• W1601694561 cites W1988649287 @default.
• W1601694561 cites W1988676151 @default.
• W1601694561 cites W1988901044 @default.
• W1601694561 cites W1990120645 @default.
• W1601694561 cites W1993998350 @default.
• W1601694561 cites W1996510724 @default.
• W1601694561 cites W1997036460 @default.
• W1601694561 cites W2000847967 @default.
• W1601694561 cites W2003638511 @default.
• W1601694561 cites W2004235635 @default.
• W1601694561 cites W2009337734 @default.
• W1601694561 cites W2011628325 @default.
• W1601694561 cites W2015595536 @default.
• W1601694561 cites W2017583911 @default.
• W1601694561 cites W2018239227 @default.
• W1601694561 cites W2022330566 @default.
• W1601694561 cites W2023555639 @default.
• W1601694561 cites W2023832104 @default.
• W1601694561 cites W2025415815 @default.
• W1601694561 cites W2030983518 @default.
• W1601694561 cites W2033825058 @default.
• W1601694561 cites W2035423348 @default.
• W1601694561 cites W2043696829 @default.
• W1601694561 cites W2043911652 @default.
• W1601694561 cites W2045209734 @default.
• W1601694561 cites W2050029097 @default.
• W1601694561 cites W2050396525 @default.
• W1601694561 cites W2060325999 @default.
• W1601694561 cites W2067279821 @default.
• W1601694561 cites W2067420088 @default.
• W1601694561 cites W2069440750 @default.
• W1601694561 cites W2071304441 @default.
• W1601694561 cites W2072082667 @default.
• W1601694561 cites W2076583198 @default.
• W1601694561 cites W2076668534 @default.
• W1601694561 cites W2078104069 @default.
• W1601694561 cites W2080063528 @default.
• W1601694561 cites W2080244053 @default.
• W1601694561 cites W2081562657 @default.
• W1601694561 cites W2083929748 @default.
• W1601694561 cites W2085686670 @default.
• W1601694561 cites W2086918041 @default.
• W1601694561 cites W2087858402 @default.
• W1601694561 cites W2091824579 @default.
• W1601694561 cites W2092998745 @default.
• W1601694561 cites W2095250951 @default.
• W1601694561 cites W2095771928 @default.
• W1601694561 cites W2098558557 @default.
• W1601694561 cites W2099088585 @default.
• W1601694561 cites W2099320502 @default.
• W1601694561 cites W2099333512 @default.
• W1601694561 cites W2099367648 @default.
• W1601694561 cites W2101500128 @default.
• W1601694561 cites W2105121109 @default.
• W1601694561 cites W2105195683 @default.
• W1601694561 cites W2105882193 @default.
• W1601694561 cites W2106181914 @default.
• W1601694561 cites W2108349673 @default.
• W1601694561 cites W2108816382 @default.
• W1601694561 cites W2108952847 @default.
• W1601694561 cites W2111465078 @default.
• W1601694561 cites W2111746410 @default.
• W1601694561 cites W2111976640 @default.
• W1601694561 cites W2114624491 @default.
• W1601694561 cites W2116388783 @default.
• W1601694561 cites W2116483002 @default.
• W1601694561 cites W2117199645 @default.
• W1601694561 cites W2117398240 @default.
• W1601694561 cites W2117692326 @default.
• W1601694561 cites W2120464557 @default.
• W1601694561 cites W2123911518 @default.
• W1601694561 cites W2124058261 @default.

• next